In 2016, iLink™ corneal cross-linking became the only FDA-approved cross-linking procedure for the treatment of progressive keratoconus. This minimally invasive outpatient procedure uses Photrexa® and Photrexa® Viscous eye drops, combined with ultraviolet (UV) light to stiffen and strengthen corneas weakened by keratoconus. Today, iLink™ remains the only FDA-approved corneal cross-linking procedure for progressive keratoconus, offering an effective treatment that can slow or halt the progression of this sight-threatening disease.
Keratoconus, often referred to as “KC,” is an eye condition in which the cornea weakens and thins over time, causing the development of a cone-like bulge and optical irregularity of the cornea. Keratoconus can result in significant visual loss and may lead to corneal transplant in severe cases.
Watch this video for a quick overview about keratoconus and how it can be treated.
Keratoconus can be treated using iLink™—the first and only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help preserve vision.
iLink™ corneal cross-linking is an innovative therapy that has transformed the treatment of progressive keratoconus. This minimally invasive outpatient procedure uses Photrexa® (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and Photrexa® Viscous riboflavin eye drops, combined with ultraviolet light from the KXL system to1:
• Create new corneal collagen cross-links
• Shorten and thicken collagen fibrils
• Stiffen and strengthen the cornea
At Todani Eye Associates, we are proud to offer the iLinkTM corneal cross-linking, the first and only FDA-approved treatment to slow or halt the progression of keratoconus and corneal ectasia following refractive surgery.